



Australian Centre for HIV and Hepatitis Virology Research (ACH2)
The Australian Centre for HIV and Hepatitis Virology Research (ACH2) is one of Australia’s four national centres for HIV and Hepatitis research and is funded by the Commonwealth Government as represented by the Department of Health and Ageing.
The purpose of the Centre is to deliver virological and immunological research outcomes of significance to improve the diagnosis, treatment and prevention of HIV and HCV in Australia and in a broader regional and international context.
WHAT IS ACH2?
ACH2 represents a continuum in research from basic virology and immunology, through to clinical and social research. The Centre encourages basic scientists, including virology and immunology researchers in HIV and hepatitis fields to translate biomedical discoveries into health care and biotechnology outcomes, and to support clinical research. The Centre has three major activities: a regular expression of interest Funding round for strategic projects; the Immunovirology Research Network (IVRN) Immunovirology Research Network for nationwide research specimen collection and redistribution for strategic research; an Annual Scientific Workshop Workshops to facilitate research collaborations.
AIMS
The Centre’s ultimate aim is to generate outcomes that will enable Australia to combat the impact of HIV, HCV and HBV locally and in the SE Asia/Pacific region. To achieve its aims, the Centre has established close relationships with the Australian Centre for Hepatitis Virology (ACHV) http://www.med.unsw.edu
Furthermore, the Centre operates as a virtual institute with open access to all HIV and hepatitis researchers in Australia.
CURRENT NEWS
REGISTRATION NOW OPEN!
ACH2
15th Annual Conference
Confirmed Dates:
4 – 6 November 2020
To Be Held Virtually
~ VIA ZOOM ~
AUSTRALIAN SNAPSHOT OF HIV – 2014
An estimated 27,150 people were living with HIV infection in Australia. There was a total of 1,081 newly diagnosed infections. HIV continued to be primarily transmitted amongst men-who-have-sex-with-men (MSM) – 70%, with a further 19% of cases attributed to heterosexual sex, 5% to sexual contact between men and injecting drug use, and 3% to injecting drug use only.
AUSTRALIAN SNAPSHOT OF HEPATITIS C – 2014
An estimated 230,470 people had chronic hepatitis C infection in Australia, of whom 185,740 people had early to moderate fibrosis and 44,730 severe fibrosis or hepatitis C related cirrhosis. There was a total of 10,621 newly diagnosed infections. Hepatitis C transmission continued to occur primarily amongst people with a recent history of injecting drug use.
AUSTRALIAN SNAPSHOT OF HEPATITIS B – 2014
An estimated 213,300 people were living with chronic hepatitis B infection in Australia, of whom 19,837 (9.3%) were Aboriginal and Torres Strait Islander peoples. There was a total of 6,635 newly diagnosed hepatitis B infections. Hepatitis B transmission continued to occur predominantly amongst people with a recent history of Injecting drug use, with higher rates in Aboriginal and Torres Strait Islander peoples than in non-Indigenous.
Source: Annual Surveillance Report, Kirby Institute, 2014